New Leadership Elected to ASH Executive Committee

Get Permission

THE AMERICAN SOCIETY OF HEMATOLOGY (ASH) announced the election of four new members to its Executive Committee for terms beginning after the 2018 ASH Annual Meeting & Exposition in December.

Martin S. Tallman, MD, will serve a 1-year term as Vice President, followed by successive terms as President-Elect and President. Mark Crowther, MD, will serve a 4-year term as Treasurer. Belinda R. Avalos, MD, and Arnold Ganser, MD, will each serve 4-year terms as Councillors.

Dr. Tallman: Vice President

DR. TALLMAN is Chief of the Leukemia Service at Memorial Sloan Kettering Cancer Center and Professor of Medicine at Weill Cornell Medical College in New York. His research interests include clinical investigation in acute myeloid leukemia, acute lymphocytic leukemia, acute promyelocytic leukemia, and hairy cell leukemia. Dr. Tallman has been a member of ASH for 20 years.

“The most important issue facing hematology today is the remarkably rapid pace of progress in the discovery, dissemination, and integration of new knowledge,” shared Dr. Tallman. “I believe that my past leadership activities in ASH will enable me to effectively contribute to the strategic decision of the Executive Committee and further ASH’s mission to promote research, clinical care, education, training, and advocacy in hematology.”

Dr. Crowther: Treasurer

DR. CROWTHER, the Treasurer-Elect, is Chair of the Department of Medicine at McMaster University in Hamilton, Ontario, Canada. His research interests include improving the quality of anticoagulant care and management of patients with high-risk thrombophilias, focusing on antiphospholipid antibody syndrome. Dr. Crowther has been a member of ASH for 24 years.

Drs. Avalos and Ganser: Councillors

DR. AVALOS, Councillor-Elect, is Vice Chair of the Department of Hematologic Oncology and Blood Disorders at the Levine Cancer Institute and Professor of Medicine at the University of North Carolina in Chapel Hill. Her research interests include hematopoiesis and mechanisms of leukemogenesis, congenital neutropenias, receptors and cell signaling, and allogeneic hematopoietic cell transplantation. She has been a member of ASH for 25 years.

Dr. Ganser, Councillor-Elect, is Professor of Hematology and Oncology and Director of the Department of Hematology, Hemostasis, Oncology, and Stem Cell Transplantation at Hannover Medical School in Germany. His research interests include translational research on hematopoiesis and leukemogenesis as well as clinical research on acute myeloid leukemia, myelodysplastic syndromes, bone marrow failure states, and stem cell transplantation. Dr. Ganser has been a member of ASH for 29 years. ■